PMID- 3872906
OWN - NLM
STAT- MEDLINE
DCOM- 19850620
LR  - 20071114
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 134
IP  - 6
DP  - 1985 Jun
TI  - Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on 
      T cell growth.
PG  - 3895-900
AB  - The influence of the route and the frequency of IL 2 administration on the 
      ability of IL 2 to induce the growth of activated T cells in vivo was evaluated. 
      Initial pharmacokinetic studies confirmed that i.v. injection of IL 2 results in 
      a relatively high peak serum concentration, but a short serum half-life. By 
      contrast, i.p. or subcutaneous (s.c.) injection of IL 2 results in a lower peak 
      concentration but a prolonged serum half-life. The bioavailability of IL 2 
      administered by these routes was assessed by measuring the in vivo growth of 
      adoptively transferred T cells that had been previously cultured long-term with 
      IL 2, because the growth of such cells in vivo has been shown to be proportional 
      to the dose of IL 2 administered. The results demonstrated that i.p., s.c., or 
      i.v. administration of IL 2 each resulted in marked donor T cell growth in vivo. 
      Thus, IL 2 can function in vivo at sites distant to the sites of injection. In 
      addition, the magnitude of T cell growth in vivo varied dependent on the route of 
      IL 2 administration and correlated with the length of time IL 2 was detectable in 
      serum, rather than the peak level achieved (i.e., IL 2 inoculated i.v. had the 
      highest peak concentration but was least effective). As suggested by these 
      findings, dividing the total dose of IL 2 into frequent low-dose injections was 
      more effective in inducing T cell growth in vivo than was dividing the total dose 
      of IL 2 into less frequent higher-dose injections. These studies confirm the 
      great potential for IL 2 to induce the growth of activated of T cells in vivo and 
      demonstrate that the rate of T cell growth reflects not only the dose but also 
      the route and timing of IL 2 administration.
FAU - Cheever, M A
AU  - Cheever MA
FAU - Thompson, J A
AU  - Thompson JA
FAU - Kern, D E
AU  - Kern DE
FAU - Greenberg, P D
AU  - Greenberg PD
LA  - eng
GR  - CA 00721/CA/NCI NIH HHS/United States
GR  - CA 30558/CA/NCI NIH HHS/United States
GR  - CA 33084/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Animals
MH  - Cell Division
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Administration Schedule
MH  - Injections, Intraperitoneal
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Interleukin-2/*administration & dosage/physiology
MH  - Kinetics
MH  - *Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - T-Lymphocytes/*cytology/immunology
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
PST - ppublish
SO  - J Immunol. 1985 Jun;134(6):3895-900.